Stephen Zoog, Ph.D., joined 澳门正规博彩十大排行平台 in 2012 and serves as Vice President of Translational Sciences & Center of Technology. In this role, Dr. Zoog leads the strategy and transition of 澳门正规博彩十大排行平台’s lead candidates from research into early development and through registration for programs in rare genetic diseases. He oversees six departments focused on non-clinical pharmacology/toxicology, clinical pharmacology, immunogenicity, bioanalytical/in vitro diagnostics, core labs and Translational Sciences Operations. Together, these functions plan and conduct IND-enabling nonclinical strategy, and support design and analysis of translational endpoints for all clinical trials. From 2014 to 2020, Dr. Zoog served as Head of Bioanalytical Sciences.
Before joining 澳门正规博彩十大排行平台, Dr. Zoog was Principal Scientist at Amgen, where he led interdisciplinary Inflammation and Oncology Biomarker teams to support patient selection and target coverage for clinical trials.
Dr. Zoog earned a B.S. degree in biochemistry and cell biology from Bucknell University and a Ph.D. in biochemistry from the University of Wisconsin-Madison. He also completed a postdoctoral fellowship in molecular immunology at Boehringer Ingelheim Pharmaceuticals. Dr. Zoog is a member of the Research and Early Development (RED) leadership team at 澳门正规博彩十大排行平台 and recently served as chair of the Worldwide Research and Development (WWRD) leadership team from 2019 to 2021.
We maximize the impact of genetic innovation to develop transformative therapies.
Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address.
Learn More Our Pipeline ⌃